Recent Publications

Emdal KB, Palacio-Escat N, Wigerup C, Eguchi A, Nilsson H, Bekker-Jensen DB, Rönnstrand L, Kazi JU, Puissant A, Itzykson R, Saez-Rodriguez J, Masson K, Blume-Jensen P, Olsen JV (2022) Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance. Cell Rep 40, 111177

Tingholm TE, Rönnstrand L and Rosenberg PA (2020) Why and how to investigate the role of protein phosphorylation in ZIP and ZnT zinc transporter activity and regulation. Cell Mol Life Sci 77, 3085-3102

Nordgaard C, Doll S, Matos ALSA, Høeberg M, Kazi JU, Friis S, Stenvang J, Rönnstrand L, Mann M, Moreira JMA (2019) Metallopeptidase Inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. Mol Oncol 13, 2646-2662

Kazi JU and Rönnstrand L (2019) FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. Physiol Rev 99, 1433-1466. Review article

Moharram SA, Shah K,  Khanum F, Rönnstrand L and Kazi JU (2019) The ALK inhibitor AZD3463 effectively inhibits growth of sorafenib-resistant acute myeloid leukemia. Blood Cancer Journal 9:5 Letter.

Kazi JU and Rönnstrand L (2019) The role of SRC family kinases in FLT3 signaling. Int J Biochem Cell Biol 107, 32-37. Review article

Li T, Deng Y, Shi Y, Tian R, Chen Y, Zou L, Kazi JU, Rönnstrand L, Feng B, Chan SO, Chan WY, Sun J, Zhao H. (2018) Bruton’s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma. Oncogene 37, 6180-6194

Sun J, Thingholm T, Højrup P, Rönnstrand L (2018) XK-related protein 5 (XKR5) is a novel negative rgulator of KIT/D816V-mediated transformation. Oncogenesis 7:48

Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, Kazi JU, Liu J, Ramakrishan R, Garcia-Ruiz C, Nance S, Gupta P, Zhang J, Rönnstrand L, Hultquist A, Downing JR, Lindkvist-Petersson K, Paulsson K, Järås M, Gruber TA, Ma J, Hagström-Andersson AK.(2018) De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nat Commun 9(1):177

Rupar K, Moharram SA, Kazi JU and Rönnstrand L(2018) SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation. Sci Rep 8, 6405

Marhäll A, Heidel F, Fischer T, Rönnstrand L.(2018) Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.Ann Hematol 97(5):773-780

Marhäll A, Kazi JU and Rönnstrand L (2017) The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation. Sci Rep 7, 13734

Phung B, Kazi JU, Lundby A, , Bergsteinsdottir K, Sun J, Goding CR ,Jönsson G, Olsen JV, Steingrímsson E and Rönnstrand L. (2017) KITD816V induces SRC-mediated tyrosine phosphorylation of MITF and altered transcription program in melanoma. Mol Cancer Res 15, 1265-1274

Kazi JU, Chougule RA, Li T, Su X, Moharram SA, Rupar K, Marhäll A, Gazi M, Sun J, Zhao H and Rönnstrand L (2017) Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD. Cell Mol Life Sci. 74, 2679-2688

Kazi, JU, Rupar K, Marhäll A, Moharram, SA, Khanum F, Shah K, Mohiuddin G, Nagaraj SRM, Sun J, Chougule RA, Rönnstrand L (2017). ABL2 suppresses FLT3-ITD-induced cell proliferation through negative regulation of AKT signaling. Oncotarget. 8, 12194-12202

Moharram SA, Chougule RA,Su X,  Li, T, Sun J, Zhao H, Rönnstrand L and Kazi JU (2016) Src-like adaptor protein 2 (SLAP2) binds to and inhibits FLT3 signaling. Oncotarget; 7, 57770-82

Lindblad O, Cordero E, Puissant A, Macaulay L, Kabir NN, Sun J, Haraldsson K, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L and Kazi JU. (2016) Aberrant Activation of the PI3K/mTOR Pathway Promotes Resistance to FLT3 Inhibition in AML. Oncogene; 35, 5119-31

Chougule, RA, Cordero, E, Moharram SA, Pietras K, Rönnstrand L and Kazi JU (2016) Expression of GADS enhances FLT3-induced mitogenic signaling. Oncotarget 7, 14112-24

Alam MW, Persson CU, Reinbothe S, Kazi JU, Rönnstrand L, Wigerup C, Ditzel HJ, Lykkesfeldt AE, Påhlman S and Jögi A (2016) HIF2alpha contributes to antiestrogen resistance via positive bilateral crosstalk with EGFR in breast cancer cells. Oncotarget. 7, 11238-50

Chougule R, Kazi JU and Rönnstrand L (2016) FYN expression potentiates FLT3-ITD-induced STAT5 signaling in acute myeloid leukemia. Oncotarget. 7, 9964-74

Lindblad O, Chougule R, Moharram SA, Kabir NN, Sun J, Kazi JU and Rönnstrand L (2015) The role of HOXB2 and HOXB3 in acute myeloid leukemia. Biochem Biophys Res Commun. 467, 742-7

Kazi JU, Kabir NN and Rönnstrand L (2015) Brain-Expressed X-linked (BEX) proteins in human cancer. BBA Reviews on Cancer. 1856, 226-33. REVIEW

Zhang J, Vakhrusheva O, Bandi SR, Demirel Ö, Kazi JU, Gomes Fernandes R, Jakobi K, Eichler A, Rönnstrand L, Rieger M, Carpino N, Serve H and Brandts CH.(2015) STS1 and STS2 are key regulators of hematopoietic stem and progenitor cells. Stem Cell Reports 5, 633-646

Lindblad O, Li T, Su X, Sun J Kabir NN, Levander F, Zhao H, Lu G, Rönnstrand L and Kazi JU (2015)  BEX1 acts as a tumor suppressor in acute myeloid leukemia. Oncotarget 6, 21395-405

Lindblad O, Kazi JU, Rönnstrand L, Sun J.(2015) PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner. Cell Mol Life Sci 72, 4399-407

Kazi JU, Kabir NN, Rönnstrand L.(2015) Role of SRC-like adaptor protein (SLAP) in immune and malignant cell signaling. Cell Mol Life Sci 72, 2535-44. REVIEW

Agarwal S, Kazi JU, Mohlin S, Påhlman S and Rönnstrand L (2015) The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V. Oncogene 34, 4581-90